Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN67,9367,96-0,73
Msft425,5425,70,00
Nokia4,3854,451,06
IBM241,52430,00
Mercedes-Benz Group AG52,6252,65-2,73
PFE24,3224,330,00
01.05.2025 10:16:41
Indexy online
AD Index online
select
AD Index online
 

  • 30.04.2025
SurModics (SRDX.O, NASDAQ Cons)
Závěr k 30.4.2025 Změna (%) Změna (USD) Objem obchodů (ks)
28,01 -9,44 -2,92 245 721
Premarket01.05.2025 10:02:23
Poslední obchod Nákup / Prodej Změna (%) Změna (USD) Objem obchodů (ks)
- 24,05 43,00 - - -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 01.05.2025
Popis společnosti
Obecné informace
Název společnostiSurmodics Inc
TickerSRDX
Kmenové akcie:Ordinary Shares
RICSRDX.O
ISIN-
Poslední známé roční výsledky30.09.2024
Poslední známé čtvrtletní výsledky31.12.2024
Počet zaměstnanců k 30.09.2024 389
Akcie v oběhu k 31.12.2024 14 294 000
MěnaUSD
Kontaktní informace
Ulice9924 W 74th St
MěstoEDEN PRAIRIE
PSČ55344
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon19 525 007 000
Fax19525007001

Business Summary: Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
Financial Summary: BRIEF: For the three months ended 31 December 2024, Surmodics Inc revenues decreased 2% to $29.9M. Net loss increased from $786K to $3.7M. Revenues reflect In Vitro Diagnostics segment decrease of 5% to $6.6M, Medical Device segment decrease of 1% to $23.3M. Higher net loss reflects Corporate segment loss increase of 73% to $5.6M, In Vitro Diagnostics segment income decrease of 6% to $2.9M.
Odvětvová klasifikace
TRBC2009Medical Equipment / Supplies / Distribution
TRBC2012Medical Equipment, Supplies & Distribution (NEC)
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSSurgical and Medical Instrument Manufacturing
NAICS2007Surgical & Medical Instrument Mfg
NAICS1997Surgical and Medical Instrument Manufacturing
SICPatent Owners And Lessors
SICSurgical And Medical Instruments



  • Poslední aktualizace: 01.05.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorGary Maharaj6127.12.201027.12.2010
Chief Financial Officer, Senior Vice President - Finance and Information TechnologyTimothy Arens57
Senior Vice President - Legal, General Counsel, SecretaryGordon Weber6113.05.202013.05.2020
Senior Vice President of Human Resources, President - In Vitro DiagnosticsJoseph Stich5908.03.2010
Senior Vice President, President - Medical Device CoatingsCharles Olson60
Senior Vice President, President - Vascular InterventionsTeryl Sides5501.11.2018